Rare cannabinoids have potential to treat skin and eye diseases
InMed Pharmaceuticals is a leader in developing rare cannabinoids and their potential to treat serious skin and eye diseases. They are a clinical-stage biopharmaceutical company developing a proprietary biosynthesis platform for the manufacturing of pharmaceutical-grade cannabinoids. In addition, they’re developing a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs. Moreover, InMed focuses in delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
The majority of pharmaceutical and academic research & development activities investigating the physiological and disease-fighting properties of cannabis revolves around the understanding of one class of biologically active ingredients, the cannabinoids. In the 1960s, several interesting compounds were isolated from the cannabis plant. There are over 100 different cannabinoids. However, the two most well-known and studied compounds in the cannabis plant also happen to be the two that occur in the largest quantity: Δ9-tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).
Biosynthesis is the process of genetically modifying an organism to produce a pharmaceutically bioactive compound; that it otherwise would not normally make. Manufacturing of pharmaceutical-grade cannabinoids remains a challenge. Especially for those that are in only trace amounts in the cannabis plant but may hold important physiological benefits in humans. Further, InMed recognizes that having a reliable source of pure, pharmaceutical-grade starting materials for its products that are bio-identical to the compounds that you can find in nature is a critical success factor for its drug development strategy.
For more information on InMed Pharmaceuticals Inc. (IN:TSX, IMLFF:OTCQX) please fill out the form below.